Tissium Secures $50 Million to Revolutionize Tissue Reconstruction and Restore Natural Function

Tissium, a trailblazer in tissue reconstruction, is thrilled to announce a remarkable funding milestone with a fresh investment of $50,000,000. Founded in 2013 to confront one of surgery’s most enduring challenges—restoring damaged tissue and regaining its natural functionality—Tissium has consistently pushed the boundaries of innovation in medical science. Born from the pioneering work at the labs of Bob Langer and Jeff Karp at MIT, Tissium’s journey began with the discovery of its first unique polymer. Since then, the company has evolved into a leader in leveraging proprietary polymers, activation technologies, and state-of-the-art delivery devices, creating a robust technology platform that has the potential to revolutionize tissue reconstruction across diverse therapeutic areas. This new funding injection will accelerate Tissium’s mission to advance its fully integrated approach to innovation, design, commercialization, and manufacturing. By bolstering both internal projects and strategic partnerships with industry frontrunners in medtech, the company is poised to expand its suite of pioneering solutions that not only mend but also restore the natural function of damaged tissues. Tissium’s commitment to transforming medical treatment paradigms, coupled with its deep expertise and industry collaborations, underscores its role in elevating patient care worldwide. This significant capital raise marks just the beginning of a new chapter that will enhance research and development initiatives, scale manufacturing capabilities, and broaden clinical outreach, ultimately paving the way for groundbreaking therapies that have the power to redefine standard surgical procedures and improve quality of life for patients globally.